Ovensa is a Canadian preclinical stage company focused on developing innovative therapies to combat cancer resistance. The company specializes in advancing its siRNA lead candidate, which targets and silences galectin 1 overexpression in the tumor microenvironment. This approach aims to improve the therapeutic outcomes of immuno-oncology treatments, specifically anti-PD-1 checkpoint inhibitors, as a combination therapy for head and neck cancer. Ovensa collaborates with pharmaceutical companies to develop precision and combination medicines through its proprietary platform, targeting specific medical indications. The company operates in the biotechnology sector, serving pharmaceutical firms and healthcare providers. Ovensa's business model revolves around research and development, strategic partnerships, and licensing agreements, generating revenue through collaborations and intellectual property rights.

Keywords: siRNA, galectin 1, immuno-oncology, checkpoint inhibitors, head and neck cancer, combination therapy, precision medicine, biotechnology, pharmaceutical collaboration, tumor microenvironment.